VR-CHOP regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
VR-CHOP regimen refers to a regimen consisting of velcade (bortezomib), rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (Vincristine), prednisone used to treat previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.[1] .
Regimen
VVelcade (Bortezomib)
RRituximab
CCyclophosphamide
HHydroxydaunorubicin (Doxorubicin)
OOncovin (Vincristine)
PPrednisone
Indications
References
- ↑ 1.0 1.1 Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM; et al. (2011). “Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma”. J Clin Oncol. 29 (6): 690–7. doi:10.1200/JCO.2010.31.1142. PMID 21189393.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH